Objective: To investigate the longitudinal changes of gut structural damage in chronically untreated HIV infection.
INTRODUCTION
It has become increasingly clear that disruption of the gut structural integrity and subsequent microbial translocation contribute to the increased inflammation seen in HIV-infected patients on antiretroviral therapy (ART). 1, 2 Despite effective viral suppression with ART, gut damage is not reversed. 3, 4 Much of the current research effort is looking at therapeutic strategies to restore gut structural integrity, in the hope of reducing non-AIDS-related comorbidities. 1, 5 The underlying mechanisms of gut structural damage are not completely understood. Once HIV infection occurs, the gut mucosa is dramatically altered in the acute phase of the infection 6 ; however, the dynamics and the extent to which this damage persists in the chronic stage of the disease are not fully elucidated.
Intestinal fatty acid-binding protein (I-FABP) has been identified as a surrogate marker of gut epithelial destruction. 7 Most of the existing literature on I-FABP has studied this marker in the setting of acute HIV infection or ART-initiation trials. Although few cross-sectional studies measured I-FABP in the setting of chronic HIV infection, 2, 8, 9 no previous data have described the longitudinal changes in I-FABP in untreated chronic infection. Furthermore, I-FABP was found to have different functions in the same type of cells, 10, 11 and conflicting data were found on the role of I-FABP in predicting mortality in the HIV population. 8, 12 In fact, we and others have recently shown 13, 14 that in HIV-naive participants initiating treatment, I-FABP increases the first 4 weeks of treatment and then stabilized for 96 weeks. These findings raise questions as to whether the increase in I-FABP with ART initiation might be due to the beneficial effect of ART on the gut, resulting in epithelial cells' regeneration or whether the increase in I-FABP reflects the natural progression of gut barrier dysfunction among HIV-infected individuals. 13 To better dissect the effects of HIV and ART on gut structural integrity and elucidate mechanistic approaches to restore gut integrity, a better understanding of the dynamics of gut wall impairment in the chronic phase of untreated HIV disease is clearly needed.
The objectives of our study were therefore to assess changes in I-FABP over 96 weeks, in a cohort of chronically HIV-infected participants naive to ART, and to study the relationships between I-FABP, HIV variables, and inflammation in the chronic stage of untreated infection.
METHODS
This analysis from a 96-week prospective cohort study examines changes over time in the gut integrity marker I-FABP in ART-naive HIV-infected adults. Eligibility criteria have been previously described. 15, 16 Briefly, HIV-infected participants older than 18 years, naive to ART, and unlikely to require ART for at least 48 weeks based on treatment guidelines at the time (ART initiation at CD4 + T-cell count ,350 cells per mm 3 ) and without known cardiovascular diseases, diabetes mellitus, and active infectious or inflammatory conditions were eligible for inclusion. Participants were recruited from University Hospitals Cleveland Medical Center (UHCMC) Cleveland, OH. Participants signed an informed consent before study entry.
STUDY EVALUATIONS
Fasting (.8 hours) blood samples were collected from participants at baseline, week 48, and week 96, and plasma samples were stored at 270°C and never thawed until analyzed. Stored plasma was used to test for highsensitivity CRP (hsCRP), fibrinogen, D-dimer, interleukin-6 (IL-6), soluble tumor necrosis factor alpha receptors (sTNFR-I and sTNFR-II), soluble vascular cell adhesion molecule-1 (VCAM-1), and soluble intercellular adhesion molecule-1 (ICAM-1) as previously described. 15, 16 Levels of I-FABP were measured by enzyme-linked immunosorbent assay in the Dahms Clinical Research Unit at UHCMC.
Statistical Analysis
Cross-sectional and longitudinal analyses were performed. Non-normally distributed biomarker values were transformed into the logarithmic scale for analysis. Descriptive summaries of absolute levels and changes in I-FABP levels from baseline to weeks 48 and 96 are presented. Wilcoxon rank-sum tests or paired t tests were used to assess changes in biomarkers over time. Associations between gut integrity markers and markers of inflammation were examined with Spearman's rank-based correlations. Linear mixedeffect model was used to examine the association between I-FABP changes with demographic and HIV variables.
RESULTS
A total of 63 participants were eligible for this analysis. At baseline, 76% of participants were male; 62% were African Americans. The median age was 40 years, and body mass index was 27 kg/m 2 ; median baseline HIV-1 RNA level was 5520 copies per milliliter, CD4 + T-cell count and nadir CD4 + T cells were 588 and 483 cells per mm 3 , respectively, and the known median duration of HIV infection was 3.3 years.
Of the 63 participants included at baseline, 21 were started on ART by their primary care provider before 96-time point and compared with ART-naive HIV-infected participants who remained until the end of the study period, participants who initiated ART before week 96 had lower baseline CD4 + T cells and viral load without any significant differences in I-FABP levels.
LONGITUDINAL CHANGES IN I-FABP, VIREMIA, AND CD4 + T-CELL COUNT
Changes in markers of inflammation and immune activation over time have been previously published. 15, 16 Median levels of I-FABP were 1388 pg/mL at baseline. There was no evidence of a change in I-FABP levels over the first 48 weeks (mean increase of +11.1 pg/mL; P = 0.2); however, a significant increase from baseline to week 96 was seen (mean increase of +333.9 pg/mL; P = 0.03). Furthermore, when limiting our analysis to the 42 participants who remained in the study, our results remain unchanged.
After adjusting or controlling for a number of important confounding risk factors (Table 1) , we estimated the longitudinal profile of I-FABP using linear mixed-effects model with a random intercept. Coefficients of week 48 are not statistically significant (P = 0.934); however, the coefficient of week 96 is marginally significant (P = 0.056). This implies that I-FABP did not change significantly between baseline and week 48, but did change significantly between baseline and week 96. We plotted (Fig. 1 ) the estimated longitudinal I-FABP profile over the study period. Interestingly, pattern of change of HIV-RNA levels seems similar to the pattern of I-FABP changes over the study period; viral replication progressively increased over time, but this increase was only significant from baseline to week 96 (mean increase of +0.23 log10 copies RNA/mL, P , 0.01). However, CD4 + T-cell count significantly decreased over time (mean decrease of 286 CD4 + T cells per mm 3 at 48 weeks and of 2124.4 cells per mm 3 at 96 weeks from baseline; both P , 0.05).
CORRELATIONS BETWEEN I-FABP, DEMO-GRAPHICS, VIREMIA, CD4+ T CELLS, AND INFLAMMATORY MARKERS AT DIFFERENT TIME POINTS
At baseline, I-FABP levels significantly correlated with age of participants (rho = 0.3, P = 0.01) and varied across sex: levels were higher in females compared with males (median I-FABP 1735.7 vs. 1360.3 pg/mL, respectively, P = 0.04). I-FABP levels were not found to be associated with CD4 + T-cell count, viral load levels, and nadir CD4 + T-cell count at early study time points (baseline and week 48). However, with disease progression, a trend-level correlation between I-FABP and CD4 + T cell (rho = 20.3, P = 0.06) was observed at week 96, and I-FABP at week 96 was strongly associated with earlier CD4 + T-cell count from week 48 (rho = 20.7; P , 0.001). Furthermore, we found that baseline I-FABP levels were significantly associated with sTNFR-II (rho = 0.4, P = 0.02) and sVCAM-1 (rho = 0.4, P , 0.01), and these associations remained significant at weeks 48 and 96.
Effect OF VIREMIA AND CD4 + T CELLS ON I-FABP PROGRESSION
In an attempt to understand the factors driving the persistent gut structural damage over time in chronically untreated infection, we first explored the association between baseline variables and changes in I-FABP levels, and then assessed the correlations between viremia, CD4 + T cells' decline, and changes in I-FABP levels.
Again, we performed a linear mixed-effect model with a random intercept to examine the association between I-FABP progression, baseline demographics, and HIV factors. Participants with lower CD4 + T-cell count had significantly more increase in their I-FABP levels over time, suggesting that continuous enterocyte damage depends on the initial immune function. Furthermore, enterocyte damage over time was higher in females and older participants (results presented in Table 1 ).
Baseline to 96 week changes in I-FABP were correlated with baseline to 96 week changes in viral load (rho = +0.4; P = 0.03) but not with CD4 + T-cell count (P = 0.7).
DISCUSSION
Gut epithelial dysfunction and subsequent microbial translocation and immune activation in HIV are the result of complex interactions between the virus and the host response.
The initial gut structural damage is known to be one of the main drivers of these interactions; however, the dynamics and the extent to which this damage persists in untreated individuals are not fully elucidated. For the first time in HIV, we measured levels of I-FABP, a plasma marker of intestinal gut damage, over a period of 96 weeks of untreated HIV infection. The key finding in our results was that I-FABP levels increased over time and were associated with viral replication in the chronic phase of untreated infection.
Structural gut damage was shown to occur rapidly and progressively in the acute phase of HIV infection, 6 as a result of a direct viral cytotoxic effect, mucosal CD4 + Tcell depletion, inflammatory destruction, and immunemediated destruction. 9, 17 Limited data are available on gut structural damage in the chronic phase of untreated infection. Previous studies have shown that enterocyte loss still occurs in the chronic stage of the disease and is associated with increased mucosal cytokine production. 1, 18 In addition, a recent cross-sectional study by Perkins et al 19 suggested that although the virus begins and reinforces the vicious cycle of enterocyte damage in the acute phase of the disease, intestinal destruction becomes independent of viral replication in the chronic phase of the infection.
The longitudinal aspect of our study allowed us to further look at the dynamics between enterocyte damage and viral replication. In contrast to what has been previously shown, 19 we found that viral replication was correlated with enterocyte damage in untreated infection, underscoring the importance of following the evolution of gut damage over time rather than relying on a snapshot to characterize enterocyte damage in chronic infection.
As for the role of CD4 + T cells on structural enterocyte damage, we did not find any association between I-FABP and CD4 + T-cell counts at baseline (when all participants had by design, a CD4 + T-cell count .350 cells per mm 3 ). However, an inverse association between I-FABP and CD4 + T cells was observed at later time points with disease progression. These observations are consistent with previous findings 3, 12, 19 and suggest that CD4 + T cells are associated with increased enterocyte damage in the advanced immune-virological stages of the disease.
Although I-FABP has been identified as a useful marker of enterocyte death in many intestinal diseases, 20, 21 its role in HIV remains unclear. In the acute phase of the infection, I-FABP levels were found to peak 2 weeks after HIV-RNA detection, and then return to baseline once viral load reaches a set point. 6, 9 Furthermore, in ART-initiation trials, I-FABP levels increased within the first few weeks of treatment and remain elevated despite effective viral suppression. 13, 14 In our cohort, elevated levels of I-FABP were associated with viral replication, worsening immune function, and systemic markers of inflammation (sTNFR-II and sVCAM-1), supporting the hypothesis that in ART-naive, chronically HIV-infected patients, circulating levels of I-FABP are associated with a worse gut structural damage and subsequent inflammation, as well as immune activation. Altogether, these findings suggest that circulating I-FABP might reflect different biological processes in different stages of HIV infection and ART status.
Our study has many advantages; most importantly, it presents longitudinal results from a unique cohort of ARTnaive participants. In fact, with the current guidelines recommending the start of ART regardless of CD4 + T-cell count, such a cohort is challenging and almost impossible to follow over time. Several limitations should be noted. Our study is an exploratory analysis and should be used to generate hypothesis to be tested with larger cohorts. Important limitations include the lack of a control group and other measures of gut integrity and microbial translocation.
In conclusion, our study showed that enterocyte damage is a continuous process in the chronic phase of untreated HIV infection and is largely dependent on viral replication. The mechanism underlying these findings is unknown and further studies will be needed to determine whether the virus exerts a direct cytotoxic effect on intestinal gut cells, or whether the destruction occurs as a consequence of virally induced inflammation and immune activation. In the chronic phase of the infection, circulating I-FABP levels were found to be associated with worse immune function, increased inflammation, and viremia.
